The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma

Hiroshi Saeki, Yasushi Toh, Masaru Morita, Masahiko Sugiyama, Kazutoyo Morita, Yasuo Sakamoto, Yuji Soejima, Kazuhito Minami, Yoshihisa Sakaguchi, Yuichiro Higaki, Satoru Uehara, Takeshi Okamura, Yoshihiko Maehara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) have been poorly documented. Patients and methods: We investigated 50 patients with synchronous and metachronous ESCC and HNSCC. We focused on the treatment results of 20 patients with synchronous ESCC and HNSCC who received simultaneous chemoradiotherapy (CRT). Results: There were 34 patients (68.0 %) with stage 0-I ESCC and 40 patients (80.0 %) with stage II-IV HNSCC. A total of 13 (26.0 %) patients underwent endoscopic mucosal resection and 28 (56.0 %) underwent CRT for ESCC, and 35 (70.0 %) of the patients with HNSCC were treated with CRT. The 5-year overall survival rates of the 50 patients with synchronous and metachronous ESCC and HNSCC was 57.8 %. For the 20 patients with synchronous ESCC and HNSCC who received simultaneous CRT, the CRT was completed in 19 (95.0 %) patients. Although grade 3-4 adverse events were observed in five (25.0 %) patients, there were no therapy-related deaths. Complete responses (CRs) of both ESCC and HNSCC were observed in ten (50.0 %) patients. The 5-year overall survival rate of the 20 patients was 60.0 %. CRs of both ESCC and HNSCC were obtained in seven (58.3 %) patients by using a cisplatin/5-FU regimen (n = 12), and in the other three (37.5 %) patients by a platinum-based monotherapy regimen (n = 8). Conclusion: The surveillance of double cancer and the use of radical treatment contributed to the favorable outcome of the patients with ESCC and HNSCC. The optimal chemotherapy regimen for simultaneous CRT remains to be determined.

Original languageEnglish
Pages (from-to)158-164
Number of pages7
JournalEsophagus
Volume9
Issue number3
DOIs
Publication statusPublished - Sep 1 2012

Fingerprint

Chemoradiotherapy
Esophageal Squamous Cell Carcinoma
Carcinoma, squamous cell of head and neck
Survival Rate
Platinum
Fluorouracil
Cisplatin
Therapeutics
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma. / Saeki, Hiroshi; Toh, Yasushi; Morita, Masaru; Sugiyama, Masahiko; Morita, Kazutoyo; Sakamoto, Yasuo; Soejima, Yuji; Minami, Kazuhito; Sakaguchi, Yoshihisa; Higaki, Yuichiro; Uehara, Satoru; Okamura, Takeshi; Maehara, Yoshihiko.

In: Esophagus, Vol. 9, No. 3, 01.09.2012, p. 158-164.

Research output: Contribution to journalArticle

Saeki, H, Toh, Y, Morita, M, Sugiyama, M, Morita, K, Sakamoto, Y, Soejima, Y, Minami, K, Sakaguchi, Y, Higaki, Y, Uehara, S, Okamura, T & Maehara, Y 2012, 'The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma', Esophagus, vol. 9, no. 3, pp. 158-164. https://doi.org/10.1007/s10388-012-0334-8
Saeki, Hiroshi ; Toh, Yasushi ; Morita, Masaru ; Sugiyama, Masahiko ; Morita, Kazutoyo ; Sakamoto, Yasuo ; Soejima, Yuji ; Minami, Kazuhito ; Sakaguchi, Yoshihisa ; Higaki, Yuichiro ; Uehara, Satoru ; Okamura, Takeshi ; Maehara, Yoshihiko. / The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma. In: Esophagus. 2012 ; Vol. 9, No. 3. pp. 158-164.
@article{c449844386794ed5963e6d22c9f9e9e6,
title = "The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma",
abstract = "Background: The treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) have been poorly documented. Patients and methods: We investigated 50 patients with synchronous and metachronous ESCC and HNSCC. We focused on the treatment results of 20 patients with synchronous ESCC and HNSCC who received simultaneous chemoradiotherapy (CRT). Results: There were 34 patients (68.0 {\%}) with stage 0-I ESCC and 40 patients (80.0 {\%}) with stage II-IV HNSCC. A total of 13 (26.0 {\%}) patients underwent endoscopic mucosal resection and 28 (56.0 {\%}) underwent CRT for ESCC, and 35 (70.0 {\%}) of the patients with HNSCC were treated with CRT. The 5-year overall survival rates of the 50 patients with synchronous and metachronous ESCC and HNSCC was 57.8 {\%}. For the 20 patients with synchronous ESCC and HNSCC who received simultaneous CRT, the CRT was completed in 19 (95.0 {\%}) patients. Although grade 3-4 adverse events were observed in five (25.0 {\%}) patients, there were no therapy-related deaths. Complete responses (CRs) of both ESCC and HNSCC were observed in ten (50.0 {\%}) patients. The 5-year overall survival rate of the 20 patients was 60.0 {\%}. CRs of both ESCC and HNSCC were obtained in seven (58.3 {\%}) patients by using a cisplatin/5-FU regimen (n = 12), and in the other three (37.5 {\%}) patients by a platinum-based monotherapy regimen (n = 8). Conclusion: The surveillance of double cancer and the use of radical treatment contributed to the favorable outcome of the patients with ESCC and HNSCC. The optimal chemotherapy regimen for simultaneous CRT remains to be determined.",
author = "Hiroshi Saeki and Yasushi Toh and Masaru Morita and Masahiko Sugiyama and Kazutoyo Morita and Yasuo Sakamoto and Yuji Soejima and Kazuhito Minami and Yoshihisa Sakaguchi and Yuichiro Higaki and Satoru Uehara and Takeshi Okamura and Yoshihiko Maehara",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s10388-012-0334-8",
language = "English",
volume = "9",
pages = "158--164",
journal = "Esophagus",
issn = "1612-9059",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma

AU - Saeki, Hiroshi

AU - Toh, Yasushi

AU - Morita, Masaru

AU - Sugiyama, Masahiko

AU - Morita, Kazutoyo

AU - Sakamoto, Yasuo

AU - Soejima, Yuji

AU - Minami, Kazuhito

AU - Sakaguchi, Yoshihisa

AU - Higaki, Yuichiro

AU - Uehara, Satoru

AU - Okamura, Takeshi

AU - Maehara, Yoshihiko

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Background: The treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) have been poorly documented. Patients and methods: We investigated 50 patients with synchronous and metachronous ESCC and HNSCC. We focused on the treatment results of 20 patients with synchronous ESCC and HNSCC who received simultaneous chemoradiotherapy (CRT). Results: There were 34 patients (68.0 %) with stage 0-I ESCC and 40 patients (80.0 %) with stage II-IV HNSCC. A total of 13 (26.0 %) patients underwent endoscopic mucosal resection and 28 (56.0 %) underwent CRT for ESCC, and 35 (70.0 %) of the patients with HNSCC were treated with CRT. The 5-year overall survival rates of the 50 patients with synchronous and metachronous ESCC and HNSCC was 57.8 %. For the 20 patients with synchronous ESCC and HNSCC who received simultaneous CRT, the CRT was completed in 19 (95.0 %) patients. Although grade 3-4 adverse events were observed in five (25.0 %) patients, there were no therapy-related deaths. Complete responses (CRs) of both ESCC and HNSCC were observed in ten (50.0 %) patients. The 5-year overall survival rate of the 20 patients was 60.0 %. CRs of both ESCC and HNSCC were obtained in seven (58.3 %) patients by using a cisplatin/5-FU regimen (n = 12), and in the other three (37.5 %) patients by a platinum-based monotherapy regimen (n = 8). Conclusion: The surveillance of double cancer and the use of radical treatment contributed to the favorable outcome of the patients with ESCC and HNSCC. The optimal chemotherapy regimen for simultaneous CRT remains to be determined.

AB - Background: The treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) have been poorly documented. Patients and methods: We investigated 50 patients with synchronous and metachronous ESCC and HNSCC. We focused on the treatment results of 20 patients with synchronous ESCC and HNSCC who received simultaneous chemoradiotherapy (CRT). Results: There were 34 patients (68.0 %) with stage 0-I ESCC and 40 patients (80.0 %) with stage II-IV HNSCC. A total of 13 (26.0 %) patients underwent endoscopic mucosal resection and 28 (56.0 %) underwent CRT for ESCC, and 35 (70.0 %) of the patients with HNSCC were treated with CRT. The 5-year overall survival rates of the 50 patients with synchronous and metachronous ESCC and HNSCC was 57.8 %. For the 20 patients with synchronous ESCC and HNSCC who received simultaneous CRT, the CRT was completed in 19 (95.0 %) patients. Although grade 3-4 adverse events were observed in five (25.0 %) patients, there were no therapy-related deaths. Complete responses (CRs) of both ESCC and HNSCC were observed in ten (50.0 %) patients. The 5-year overall survival rate of the 20 patients was 60.0 %. CRs of both ESCC and HNSCC were obtained in seven (58.3 %) patients by using a cisplatin/5-FU regimen (n = 12), and in the other three (37.5 %) patients by a platinum-based monotherapy regimen (n = 8). Conclusion: The surveillance of double cancer and the use of radical treatment contributed to the favorable outcome of the patients with ESCC and HNSCC. The optimal chemotherapy regimen for simultaneous CRT remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=84871271880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871271880&partnerID=8YFLogxK

U2 - 10.1007/s10388-012-0334-8

DO - 10.1007/s10388-012-0334-8

M3 - Article

AN - SCOPUS:84871271880

VL - 9

SP - 158

EP - 164

JO - Esophagus

JF - Esophagus

SN - 1612-9059

IS - 3

ER -